Company Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-12 pm EST			5-day change	1st Jan Change
7.210 ^USD	-1.23%		+1.69%	-47.41%

Nov. 26	Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	MT
Nov. 25	Myriad Genetics Collaborates With Clairity, MagView to Roll Out AI Platform for Breast Cancer Risk Assessment	MT

Business description: Myriad Genetics, Inc.

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Number of employees: 2,700

Sales by Activity: Myriad Genetics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Biotechnology	-	691M	678M	753M	838M
Other	56.2M	-	-	-	-
Diagnostics	543M	-	-	-	-

See all business segments

Geographical breakdown of sales: Myriad Genetics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
United States	551M	604M	592M	118M	770M
Rest of world	48.8M	86.9M	86.9M	1.3M	68.1M

See all geographic segments

Executive Committee: Myriad Genetics, Inc.

Manager	Title	Age	Since
Samraat Raha CEO	Chief Executive Officer	53	2025-04-29
Benjamin Wheeler DFI	Director of Finance/CFO	42	2025-08-15
Dale Muzzey CTO	Chief Tech/Sci/R&D Officer	45	2014-03-31
Kevin Haas CTO	Chief Tech/Sci/R&D Officer	39	2021-01-31
Mark Verratti COO	Chief Operating Officer	56	2025-04-29

See MYRIAD GENETICS, INC. governance

Composition of the Board of Directors: Myriad Genetics, Inc.

Director	Title	Age	Since
S. Phanstiel CHM	Chairman	66	2020-03-22
Heiner Dreismann BRD	Director/Board Member	70	2010-06-09
Colleen Reitan BRD	Director/Board Member	65	2019-09-24
Lee Newcomer BRD	Director/Board Member	72	2019-09-24
Daniel Skovronsky BRD	Director/Board Member	51	2020-07-20
Rashmi Kumar BRD	Director/Board Member	54	2020-09-09
Paul Bisaro BRD	Director/Board Member	64	2022-10-30
Samraat Raha BRD	Director/Board Member	53	2025-04-29
Mark Davis BRD	Director/Board Member	62	2024-12-09

Composition of the Board of Directors

Shareholders: Myriad Genetics, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 15.06 %	14,041,203	15.06 %	107 M $
Vanguard Fiduciary Trust Co. 8.456 %	7,882,515	8.456 %	60 M $
STATE STREET CORPORATION 5.339 %	4,976,492	5.339 %	38 M $
Millennium Management LLC 5.094 %	4,748,327	5.094 %	36 M $
Glenview Capital Management LLC 4.921 %	4,587,407	4.921 %	35 M $

List of MYRIAD GENETICS, INC. shareholders

Company details: Myriad Genetics, Inc.

Myriad Genetics, Inc.

322 North 2200 West

84116, Salt Lake City

+801 584 3600

http://www.myriad.com

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MYRIAD GENETICS, INC.	-1.23%	+1.69%	-50.03%	-58.92%	672M
BIOMÉRIEUX	-0.19%	+2.49%	+5.63%	+8.59%	14.84B
GUARDANT HEALTH, INC.	+0.68%	+0.05%	+193.64%	+141.64%	13.15B
CARIS LIFE SCIENCES, INC.	+0.83%	-7.28%	-	-	7.55B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.14%	-2.66%	-17.22%	+24.13%	6.49B
LANTHEUS HOLDINGS, INC.	+5.58%	+5.24%	-28.38%	+22.46%	4.42B
DIASORIN S.P.A.	-1.88%	+1.39%	-38.48%	-53.48%	4.03B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.28%	-1.85%	-21.47%	-40.39%	2.87B
BEIJING HOTGEN BIOTECH CO., LTD.	+3.00%	+16.83%	+261.10%	+153.58%	2.54B
ANDON HEALTH CO., LTD.	+0.07%	-1.30%	-6.26%	-31.86%	2.4B
Average	+0.71%	+1.18%	+33.17%	+18.42%	5.9B
Weighted average by Cap.	+0.62%	+0.41%	+54.27%	+42.56%